XI Congresso della Società Italiana di Psicopatologia Psichiatria ...

62. Il riconoscimento delle espressioni
facciali in un campione di pazienti
con schizofrenia
G. Cerroni, D. Mirabilio, S. Di Tommaso, M. Aniello,
P. Valente, M. Di Pietro, A. Rossi
Dipartimento di Medicina Sperimentale, Università de L’Aquila
Introduzione: l’alterato riconoscimento delle espressioni
facciali (REF) nei pazienti schizofrenici contribuisce ad un
funzionamento sociale deficitario e potrebbe predire un loro
scarso funzionamento cognitivo (Benoit et al., 2005).
Obiettivo: scopo dello studio è di valutare il REF in una popolazione
di pazienti con diagnosi di schizofrenia.
Metodo: dieci pazienti schizofrenici, confrontati con un
gruppo di controllo di venti soggetti, sono stati valutati con
il test per la discriminazione emotiva di Ekman e Friesen
(1976) che presentava 36 foto caratterizzate da 6 emozioni
base di felicità, tristezza, paura, rabbia, sorpresa e disgusto.
Inoltre sono stati somministrati il Symptom Check List
(SCL-90), il Millon Clinical Multiaxial Inventory (MCMI-
III) e la Positive and Negative Syndrome Scale (PANSS) per
analizzare la psicopatologia attuale.
Risultati: i pazienti schizofrenici hanno ottenuto un basso
punteggio rispetto al gruppo di controllo nel compito di riconoscimento
delle espressioni emotive, particolarmente
nella discriminazione della paura e del disgusto.
Conclusioni: il nostro studio conferma che riconoscimento
delle espressioni facciali è alterato nella schizofrenia. In base
ai risultati dei recenti studi che affermano l’esistenza di
un circuito neurale dedicato al riconoscimento dei volti e
delle emozioni espresse mediante la mimica facciale (es. giro
fusiforme e le regioni più anteriori e dorsali del lobo temporale)
si potrebbe quindi ipotizzare che nei pazienti schizofrenici
vi è un deficit in tale sistema.
Bibliografia
Benoit B, Krolak- Salmon P, Saoud M, Henaff MA, Burt M, Dalery
J, et al. Facial Expression and Sex Recognition in Schizophrenia
and Depression. Can J Psychiatry 2005;50:525-33.
Ekman P, Friesen WV. Pictures of Facial Affect. Palo Alto, CA:
Consulting Psychologists Press 1976.
63. Amisulpride in Treatment Resistant
Schizoaffective Disorder
C. Cimmino, G. Foggia, I. Celentano, G. Barra, C. Ciliberti,
A. Rocco, T. Cante, M. Romano, E. Mauro
Psychiatry Emergency Hospital “San Giovanni di Dio”,
Frattaminore, Napoli
Background: there are not data in the literature regarding
amisulpride use in resistant schizoaffective disorder.
The objective of this study was to evaluate the efficacy and
safety of amisulpride in treatment Resistant Schizoaffective
Disorder.
This analysis aimed to assess clinical response to amisulpride
treatment in patients with resistant Schizoaffective
Disorder.
Method: a total of 22 patients diagnosed with schizoaffective
disorder according to DSM-IV TR criteria and having a
253
POSTER
history of resistance to treatment with other antipsychotics
were included in the study.
The mean amisulpride dose was 600 mg/day and 800
mg/day.
The patients were assessed for Psychotic symptoms with the
Positive and Negative Syndrome Scale (PANSS) at baseline
and at week 12 of amisulpride treatment; for movement disorders
with the Extrapyramidal Symptom Rating Scale
(ESRS); for adverse events (AEs) were reported spontaneously;
for depressive symptoms with HAMD and
MADRS; with Psychiatric Rating Scale (BPRS) and CGI.
Amisulpride was added to other medications, but other antipsychotics.
Results: there was a significant effect of treatment on improvement
in PANSS total scores from baseline to endpoint.
(69% reduction of positive symptoms in the PANSS positive
subscale and negative symptoms 75% reduction of negative
symptoms in the PANSS negative subscale; p = 0.001).
The reduction in HAMDscores between the baseline (25.6 ±
4.1) and the endpoint (4.2 ± 2.3) was statistically significant
(p = 0.002).
The most commonly observed side effects included asthenia
(6 patients, 26%), weight gain (3 patients, 15%), and mild
sedation (5 patients, 25%).
Marked improvement in CGI after 12 week of treatment
was observed in 22 (100%) patients.
Conclusions: this study suggests that amisulpride may be a
an effective and well tolerated drug for treatment resistant
schizoaffective disorder.
64. Effectiveness and tolerability
of amisulpride in Bipolar Disorder I,
treatment of bipolar mania: results of a 24week
open study
C. Cimmino, G. Foggia, I. Celentano, G. Barra, C. Ciliberti,
A. Rocco, T. Cante, M. Romano, E. Mauro
Psychiatry Emergency Hospital, “San Giovanni di Dio”,
Frattaminore, Napoli
Background: amisulpride (Solian), a substituted benzamide
derivative, is a second-generation antipsychotic that
preferentially binds to dopamine D2/D3 receptors in limbic
rather than striatal structures. High dosages preferentially
antagonise postsynaptic D2/D3 receptors, resulting in reduced
dopamine transmission, and low dosages preferentially
block presynaptic D2/D3 receptors, resulting in enhanced
dopamine transmission. Amisulpride has been reported
to be effective in the treatment of schizophrenia and
major depressive disorder.
Method: this was a single-blind clinical trial involving 41
subjects suffering from Bipolar Disorder I, manic phase to a
24-week treatment with Amisulpride (600 mg/day increased
to 800 mg after 7 days of treatment). The sample of 13 females
(F = 31%; mean age 32.4 ± 1.2) and 28 males (M =
69%;mean age 39.1 ± 2.2) consecutively admitted in the
Center for the study of Mood Disorders was recruited in
Emergency Psychiatric Hospital with a DSM-IV TR diagnosis
of Bipolar Disorder I, manic phase.
The sample was assessed by Young Mania Rating Scale
(YMRS) total score 20.